Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
AssigneeRoche GlyeArt AG
InventorsPablo Umaña, Joël Jean-Mairet, James E. Bailey
Life of this patent
Estimating the term…
Abstract
The present invention relates to the field glycosylation engineering of proteins. More particular, the present invention is directed to the glycosylation engineering of proteins to provide proteins with improved therapeutic properties, e.g., antibodies, antibody fragments, or a fusion protein that includes a region equivalent to the Fc region of an immunoglobulin, with enhanced Fc-mediated cellular cytotoxicity.
Claims29
A glycoengineered, recombinant antibody comprising an IgG Fc region containing N-linked oligosaccharides, wherein said antibody is isolated from a Chinese Hamster Ovary host cell and has been engineered to have an increased ratio of GlcNAc residues to fucose residues in the Fc region compared to a corresponding antibody produced by a Chinese Hamster Ovary host cell that has not been glycoengineered, and wherein said antibody has increased Fc-mediated cellular cytotoxicity as a result of said glycoengineering.
Dependencies are inferred from the claim text.